Scientists using elevated levels of vitamin C were able to kill certain kinds of colorectal cancer cells, according to a new study. This breakthrough discovery suggests that scientists may be able to harness vitamin C to develop new cancer treatments.
On Nov. 5, Science published this recent study on vitamin C cancer therapy conducted by researchers and scientists from Weill Cornell Medicine, Cold Spring Harbor Laboratory, Tufts Medical Center, Harvard Medical School, and Johns Hopkins Kimmel Cancer Center. The team found that high doses of vitamin C stopped the growth of mutant colorectal cancer tumors in cultured cells and mice.
In killing the colorectal cancer cells, researchers used high levels of vitamin C doses nearly equal to the levels found in 300 oranges. This new finding could lead to the development of new treatments and offer important information into who would most benefit from them.
Even though this latest study is very promising, having made some major headway in fighting colorectal cancer, Dr. Lewis Cantley, senior author and Meyer Director of the Sandra and Edward Meyer Cancer Center and the Margaret and Herman Sokol Professor in Oncology Research at Weill Cornell Medicine, suggests vitamin C and its effect on colorectal cancer should be studied further.
"Our findings provide a mechanistic rationale for exploring the therapeutic use of vitamin C to treat colorectal cancers that carry KRAS or BRAF mutations."
Most health experts are aware of how vitamin C is able to improve health, partly because it can act as an antioxidant, as well as delay or prevent various types of cell damage. However, Dr. Cantley and his team of scientists and researchers discovered that the opposite was true for high-dose vitamin C's therapeutic effects for the KRAS and BRAF forms of colorectal cancer. They found that the mutant KRAS and BRAF tumors occur as a result of inducing oxidation in these cancer cells.
Dr. Cantley points out that, though the recent findings by his colleagues on vitamin C and its effect on colorectal cancer tumors are promising, the need for additional evaluations in the setting of a human clinical trial are necessary. Nevertheless, the pre-clinical findings may offer a promising new treatment strategy for the KRAS or BRAF forms of the disease.
The lead author of this latest study on vitamin C and colorectal cancer, Dr. Jihye Yun, agrees with Dr. Cantley that caution must be observed concerning this new finding.
"Further study is definitely needed to expand our understanding of these processes. But now that we know the mechanisms, we can utilize the knowledge wisely to get the desired effects."
"This is not a therapy that you would want to wander into blindly without knowledge of what is going on in your tumor."
In the recent phase I clinical trials conducted on humans, researchers found that the intravenous infusion of vitamin C, at doses that converted to similar levels in Dr. Cantley's mice trials, had good safety profiles.
Dr. Yun hopes their recent study on vitamin C and cancer therapy will motivate others to pursue additional avenues of research.
"Our hope is that our study will inspire the scientific community to take a fresh look at this safe and inexpensive natural molecule and stimulate both basic and clinical research regarding vitamin C as a cancer therapy."